B Cell-Targeted Therapy for Rheumatoid Arthritis
- 1 January 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 66 (5), 625-639
- https://doi.org/10.2165/00003495-200666050-00004
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Use of intravenous immunoglobulin G (IVIG)Best Practice & Research Clinical Haematology, 2006
- Natural antibodies sustain differentiation and maturation of human dendritic cellsProceedings of the National Academy of Sciences of the United States of America, 2004
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Rituximab treatment results in impaired secondary humoral immune responsivenessBlood, 2002
- Rituximab: Mechanism of action and resistanceSeminars in Oncology, 2002
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritidesArthritis & Rheumatism, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisThe New England Journal of Medicine, 2000
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.2000
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.1994